SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Hepatitis C. Available at http://www.who.int/mediacentre/factsheets/fs164/en/ Last accessed 25 July 2005.
  • 2
    Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 6009.
  • 3
    Lee SS. Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 61121.
  • 4
    Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 37081.
  • 5
    Foster GR, Fried MW, Hadziyannis SJ, Chaneac M. Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) (PEGASYS (R) and ribavirin (COPEGUS (R): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology 2003; 38 (Suppl. 1): 246A.
  • 6
    Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic–pharmacodynamic models. Clin Pharmacol Ther 2002; 72: 34961.
  • 7
    Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 55565.
  • 8
    Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47: 1249.
  • 9
    Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepatol 2004; 11: 847.
  • 10
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 2759.
  • 11
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhurmeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 12
    Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Berstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill A, Pegasys International Study Group. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. Randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 13
    Hastie TJ, Tibshirani RJ. Generalized Additive Models. Monographs on Statistics and Applied Probability 43. London: Chapman & Hall 1990.
  • 14
    Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; in press.
  • 15
    Sakamoto Y, Ishiguro M, Kitagawa G. Akaike Information Criterion Statistics: D. Dordrecht: Reidel Publishing Co. 1986.
  • 16
    Efron B, Tibshirani RJ. An Introduction to the Bootstrap. San Francisco: Chapman & Hall 1993.
  • 17
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 18
    Brown RS Jr, Jacobson IM, Afdhal N, Freilich B, Pauley BP, Regenstein F, Flamm S, Kwo P, Griffel L, Brass CA and the WIN-R Study Group. Differences in Treatment Outcome to Antiviral Therapy Based on Genotype and Viral Load in Hepatitis C Genotypes 2 and 3 in the WIN-R Trial. EASL 2006 Congress Abstract 41.
  • 19
    Rendon AL, Nunez M, Romero M, Barreiro P, Martin-Carbonero L, Garcia-Samaniego J, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39: 4015.
  • 20
    Maeda Y, Kiribayashi Y, Moriya T, Maruhashi A, Omoda K, Funakoshi S, Murakami T, Takano M. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004; 26: 915.
  • 21
    Zeuzem S. Heterogenous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 37081.